SiBone (NASDAQ:SIBN) Insider Sells $108,787.80 in Stock

SiBone (NASDAQ:SIBN – Get Free Report) insider Anshul Maheshwari sold 4,665 shares of the company’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $23.32, for a total transaction of $108,787.80. Following the completion of the sale, the insider directly owned 206,585 shares in the company, valued at $4,817,562.20. This trade represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

  • On Tuesday, November 17th, Anshul Maheshwari sold 1,715 shares of SiBone stock. The stock was sold at an average price of $23.19, for a total transaction of $39,770.85.
  • On Wednesday, November 4th, Anshul Maheshwari sold 3,247 shares of SiBone stock. The stock was sold at an average price of $25.00, for a total transaction of $81,175.00.
  • On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total transaction of $84,105.00.
  • On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The shares were sold at an average price of $19.50, for a total transaction of $33,754.50.
  • On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total transaction of $60,321.24.
  • On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total value of $233,999.96.
  • On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $224,784.56.

SiBone Stock Performance

Shares of SIBN stock opened at $23.73 on Friday. The stock has a market cap of $1.07 billion, a PE ratio of -76.55 and a beta of 0.64. The business has a 50-day simple moving average of $20.88 and a 200-day simple moving average of $16.96. The company has a quick ratio of 6.15, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. SiBone has a 52-week low of $11.48 and a 52-week high of $25.92.

SiBone (NASDAQ:SIBN – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.05. The firm had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. On average, equities analysts expect that SiBone will post -0.34 EPS for the current year.

Hedge Funds Weigh In On SiBone

Institutional investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC increased its stake in shares of SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after acquiring an additional 2,774,795 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of SiBone by 0.4% in the third quarter. American Century Companies Inc. now owns 2,520,834 shares of the company’s stock valued at $47,392,000 after purchasing an additional 9,871 shares during the period. Granahan Investment Management LLC grew its holdings in shares of SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after purchasing an additional 858,942 shares during the period. Paradigm Capital Management Inc. NY increased its position in SiBone by 113.3% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after purchasing an additional 598,300 shares during the last quarter. Finally, Marshall Wace LLP increased its position in SiBone by 1.2% during the third quarter. Marshall Wace LLP now owns 698,416 shares of the company’s stock worth $13,130,000 after purchasing an additional 8,128 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on SIBN. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a research report on Wednesday. Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Needham & Company LLC cut their price target on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a report on Tuesday, November 3rd. Truist Financial raised their price target on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Finally, Citigroup reiterated a “market outperform” rating on shares of SiBone in a report on Tuesday, November 3rd. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.00.

View Our Latest Research Report on SIBN

SiBone Company Profile

(Get Free Report)

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.

Recommended Stories

Insider Buying and Selling by Quarter for SiBone (NASDAQ:SIBN)

Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.